01. Acute coronary syndromes
02. Angiogenesis
03. Atherosclerosis
04. Arrhythmia
05. Cardiomyopathy
06. Endothelial function
07. Fibrillation
08. Genetics
09. Heart Failure
10. Hypertension
11. Myocardial infarction
12. Myocardial Ischemia
13. Myocarditis
14. Signal Transduction in Smooth Muscle
15. Stroke
16. Stunned myocardium
17. Thrombus
18. Valvular heart disease
19. Vasculitis
2. An ischemia-guided approach for risk stratification in patients
3. Antithrombotic Therapy in Patients With Acute Coronary Syndromes-1
4. Antithrombotic Therapy in Patients With Acute Coronary Syndromes
5. Avoidance of routine revascularization in the management of patients with non-ST-segment elevation
6. Calming the plaque to delay intervention for 24 hours
7. Defining the optimal pharmacotherapy of non：CST-segment elevation (NSTE) acute coronary syndromes (ACS)
8. Defining the role of abciximab for acute coronary syndromes
9. extending medical intervention for five days before proceeding to revascularization
10. Guidelines for acute coronary syndromes
11. Inflammatory role of platelets in acute coronary syndromes
12. Low-Molecular-Weight Heparins in the Treatment of Acute Coronary Syndromes
13. Management of Acute Coronary Syndromes
14. New advances in the management of acute coronary syndromes 2. Fibrinolytic therapy for acute ST-segment elevation myocardial infarction
15. New advances in the management of acute coronary syndromes-2
16. New advances in the management of acute coronary syndromes-3. The role of catheter-based procedures
17. Small peptide GP IIb-IIIa receptor inhibitors as upstream therapy in acute coronary syndromes
18. Strategies of patient care
19. Sudden cardiac death-
20. The role of low-molecular-weight heparin in the management of acute coronary syndromes
21. Therapeutic adjuncts for immediate transfer to the catheterization laboratory
22. Thrombosis prophylaxis in the acutely ill medical patient
2. Angiogenesis in hematologic malignancies
3. Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation
4. Angiomotin Regulates Endothelial Cell Motility
5. Antibody-Based Targeting of Angiogenesis
6. ephrins and Eph receptors in angiogenesis
7. Functionally Active VEGF Fusion Proteins
8. Inhibition of Glioma Angiogenesis and Growth in Vivo by Systemic Treatment with a Monoclonal Antibody against Vascular Endothelial Growth Factor Receptor-2
9. Integrating the VEGF Signals Leading to Actin-Based Motility in Vascular Endothelial Cells
10. l-In Vitro Models of Vasculogenesis and Angiogenesis
11. Regulation of angiogenesis in the endometrium
12. Revascularization for cardiogenic shock
13. revascularization-Cholesterol lowering in atherosclerosis
14. revascularization-Foreword
15. revascularization-Introduction-
16. revascularization-Introduction-comparative pathobiology of atherosclerosis and restenosis
17. revascularization-Lipid-lowering therapy after coronary revascularization
18. revascularization-Rationale for a postintervention continuum of care-insights from intravascular ultrasound
19. Role of Id Proteins in Embryonic and Tumor Angiogenesis
20. ephrins and Eph receptors in angiogenesis
21. Pulmonary complications after coronary revascularization
22. Signal transduction by VEGF receptor-1 wild type and mutant
2. A simple method to assess the oxidative susceptibility of low density lipoproteins
3. Advances in Experimental Dyslipidemia and Atherosclerosis
4. An unsolved mystery of promoter variation in CETP gene and atherosclerosis
5. Analytical models of atherosclerosis
6. Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis
7. Antibodies against oxidized LDL for non-invasive diagnosis of atherosclerotic vascular disease
8. Antioxidants and atherosclerotic cardiovascular disease
9. Atherosclerosis as an autoimmune disease-an update
10. Atherosclerotic renovascular disease-diagnosis and treatment
11. Biomechanical-stress-induced Signaling and Gene Expression in the Development of Arteriosclerosis
12. Building a brain attack team to administer thrombolytic therapy for acute ischemic stroke
13. C-Reactive protein, oxidative stress, homocysteine, and troponin and atherosclerosis
14. Carotid angioplasty and stenting-current status
15. CD36-a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism
16. CD40 Signaling and Plaque Instability
17. Characterization of atherosclerotic plaque by magnetic resonance imaging
18. Chemokines-the link between inflammation, restenosis and atherosclerosis
19. Chlamydia pneumonia (and other infective agents) in atherosclerosis and acute coronary syndromes
20. Chlamydia pneumoniae and Atherosclerosis
21. Class B Scavenger Receptors, Caveolae and Cholesterol Homeostasis
22. Clinical Imaging of the High-Risk or Vulnerable Atherosclerotic Plaque
23. Contribution of Adventitial Fibroblasts to Neointima Formation and Vascular Remodeling
24. Decorin Links Low-Density Lipoproteins (LDL) to Collagen; A Novel Mechanism for Retention of LDL in the Atherosclerotic Plaque
25. Design of the Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial
26. Domains of Apolipoprotein E Involved in the Binding to the Protein Core of Biglycan of the Vascular Extracellular Matrix
27. Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis
28. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis
29. Endogenous heparin activity deficiency-the `Missing Link' in atherogenesis
30. Estrogen in the Prevention of Atherosclerosis
31. Experimental atherosclerosis= A historical overview
32. Guideline-The Lower the Better in Hypercholesterolemia Therapy-A Reliable Clinical Guideline
33. guidelines-Current guidelines for the management of unstable angina-a new diagnostic and management paradigm
34. Heat shock proteins and atherosclerosis
35. Immune Mechanisms in Atherosclerosis
36. Impact of Coronary Heart Disease on World Leaders
37. Impaired Homocysteine Metabolism and Atherothrombotic Disease
38. Influence of Caveolin, Cholesterol, and Lipoproteins on Nitric Oxide Synthase; Implications for Vascular Disease
39. Ischemic heart disease-Adjunctive pharmacotherapy for coronary stenting
40. Ischemic heart disease-Angiogenesis and the ischaemic heart
41. Ischemic heart disease-Evolving concepts of vulnerable plaque and surgical and percutaneous methods of revascularization
42. Ischemic heart disease-Haematocrit, viscosity, erythrocyte sedimentation rate-coronary heart disease
43. Ischemic heart disease-Minimally invasive CABG
44. Ischemic heart disease-Multivessel coronary artery disease-current revascularization strategies
45. Ischemic heart disease-Patients, families and populations at high risk for coronary heart disease
46. Ischemic heart disease-Role of cytokines in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty
47. Ischemic heart disease-The 6-minute walk. A simple test with clinical application
48. Ischemic heart disease-The use of mechanical devices as adjuncts to intracoronary stenting
49. Ischemic heart disease-Transmyocardial laser revascularization
50. Lipoprotein Modulation of Subendothelial Heparan Sulfate Proteoglycans (Perlecan) and Atherogenicity
51. Low-Density Lipoprotein Size, Pravastatin Treatment, and Coronary Events
52. Lp A-I and Niacin-New Views of an Antiatherogenic Duo
53. LRP-a multifunctional scavenger and signaling receptor
54. Major risk factors and coronary heart disease
55. Manipulating the vascular biology of coronary atherosclerosis in diabetes
56. Methylenetetrahydrofolate reductase genotypes and predisposition to atherothrombotic disease
57. Multivessel coronary artery disease-current revascularization strategies
58. New insights into atherosclerotic plaque rupture
59. Oxidized LDL and HDL-antagonists in atherothrombosis
60. p73 is a growth-regulated protein in vascular smooth muscle cells and is present at high levels in human atherosclerotic plaque
61. Pathophysiological Events during Pregnancy Influence the Development of Atherosclerosis in Humans
62. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis
63. Plaque cholesterol and calcium-the value of EBCT in the detection of coronary atherosclerosis
64. Platelet polymorphisms and ischemic heart disease-moving beyond traditional risk factors
65. Platelets and the Injured Vessel Wall-Rolling into Action
66. Potential roles of the peroxisome proliferator-activated receptor g in macrophage biology and atherosclerosis
67. PPAR and Atherosclerosis-Effects on Cell Growth and Movement
68. Primary Prevention of Coronary Heart Disease
69. Renal failure in atherosclerotic renovascular disease
70. Role of apoA-II in lipid metabolism and atherosclerosis
71. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems
72. scavenger receptor-class A macrophage scavenger receptor (SR-A) multifunctional
73. scavenger receptor-Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems
74. Screening for subclinical deep-vein thrombosis
75. Sialyltransferase activity of human plasma and aortic intima is enhanced in atherosclerosis
76. Smooth muscle cells in coronary atherosclerotic plaques-phenotypic variation
77. studies of the NAD(P)H oxidase in atherosclerosis
78. The smooth muscle cell membrane during atherogenesis
79. thyroid, blood flow and atheroma
80. Troponin measurements in ischemic heart disease
81. Tumor Necrosis Factor Receptor and Ligand Superfamily Family Members TNFRSF14 and LIGHT-New Players in Human Atherogenesis
82. Tumor Necrosis Factor Receptor Levels Are Associated With Carotid Atherosclerosis
83. Tumor Necrosis Factor Receptor Superfamily 14 Is Involved in Atherogenesis by Inducing Proinflammatory Cytokines and Matrix Metalloproteinases
2. Advances in implantable cardioverter defibrillators
3. Algorithms useful in the treatment of atrial fibrillation
4. Biventricular pacing in congestive heart failure-a boost toward finer living
5. Catheter ablation of atrial flutter and macroreentrant atrial tachycardia
6. Current clinical perspectives on implantable devices for atrial defibrillation
7. Implantable cardioverter defibrillator trials-what's new
8. Pacing for the prevention of atrial fibrillation
9. Permanent cardiac pacing to prevent vasovagal syncope
10. T wave alternans for ventricular arrhythmia risk stratification
11. underlying the long QT syndrome-Cellular mechanisms
12. underlying the long QT syndrome-Molecular mechanisms
13. Social and psychosocial influences on sudden cardiac death, ventricular arrhythmia
14. Autoantibodies-Emerging Upstream Targets of Arrhythmias and Sudden Death
15. Antiarrhythmic drugs in pregnancy-1
16. Antiarrhythmic drugs in pregnancy
17. arrhythmias-Basic mechanisms of reentrant arrhythmias
18. Arrhythmogenic Right Ventricular Dysplasia-1
19. Arrhythmogenic Right Ventricular Dysplasia
20. Atrial fibrillation-rate control versus maintenance of sinus rhythm-1
21. Atrial fibrillation-rate control versus maintenance of sinus rhythm
22. Basic mechanisms of reentrant arrhythmias
23. Current Status of the Implantable Cardioverter-Defibrillator
24. Function and structure of the mouse sinus node
25. Intravenous antiarrhythmic agents
26. Issues in the use of generic antiarrhythmic drugs
27. Management of implantable cardioverter defibrillator patients-1
28. Management of implantable cardioverter defibrillator patients
29. management of surgical complications of pacemaker and implantable cardioverter-defibrillators-1
30. ntravenous antiarrhythmic agents
31. Reperfusion Arrhythmias-New Insights into the Role of the Na+-Ca2+Exchanger
32. sues in the use of generic antiarrhythmic drugs-1
33. The management of surgical complications of pacemaker and implantable cardioverter-defibrillators
34. Update on external cardioversion and defibrillation-1
35. Update on external cardioversion and defibrillation
36. Use of implantable pacemakers and implantable defibrillators in hypertrophic cardiomyopathy-1
37. Use of implantable pacemakers and implantable defibrillators in hypertrophic cardiomyopathy
38. Ventricular arrhythmias in the athlete-1
39. Ventricular arrhythmias in the athlete
40. Arrhythmic risk stratification of post：Cmyocardial infarction patients
41. Catheter ablation in the year 2000
42. Classification system of atrial fibrillation
43. Clinical implication of antiembolic trials in atrial fibrillation
44. Cost-effective strategies in the acute management of atrial fibrillation
45. Inherited Sodium Channelopathies_ Novel Therapeutic and Proarrhythmic
46. Inpatient versus outpatient antiarrhythmic drug initiation
47. New advances in class III antiarrhythmic drug therapy
48. Arrhythmogenic Ionic Remodeling
2. The diagnosis of hypertrophic cardiomyopathy
3. Activation of the Small GTP-binding Protein Ras in the Heart by Hypertrophic Agonists
4. Angiotensin II Type 2 Receptors and Cardiac Hypertrophy
5. Athlete's Heart Electrocardiogram Mimicking Hypertrophic Cardiomyopathy
6. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF-Metalloproteinase inhibitors as a new therapy
7. Cirrhotic cardiomyopathy-a pathophysiological review of circulatory dysfunction in liver disease
8. Clinical Significance of Atrial Fibrillation in Hypertrophic Cardiomyopathy
9. Contractile Dysfunction in Hypertrophic Cardiomyopathy_Elucidating Primary Defects of Mutant Contractile Proteins by gene transfer
10. Current Status of Alcohol Septal Ablation for Patients with Hypertrophic Cardiomyopathy
11. Different expressivity of myosin light chain gene Ala57Gly mutation in hypertrophic cardiomyopathy
12. Dual Effects of Angiotensin II Type 2 Receptor on Cardiovascular Hypertrophy-1
13. Dual Effects of Angiotensin II Type 2 Receptor on Cardiovascular Hypertrophy
14. Dual-Chamber Pacing In Hypertrophic Cardiomyopathy
15. Genetic Abnormalities Responsible For Dilated Cardiomyopathy
16. Human eHAND, but not dHAND, is Down-regulated in Cardiomyopathies
17. Inducible Activation of c-Myc in Adult Myocardium In Vivo Provokes Cardiac Myocyte Hypertrophy
18. Insights into Pathogenesis and Treatment of Cytokines in Cardiomyopathy
19. Molecular Genetics of Hypertrophic Cardiomyopathy
20. myosin light chain gene Ala57Gly mutation in familial hypertrophic cardiomyopathy
21. Prognostic implications of left ventricular hypertrophy-1
22. Prognostic implications of left ventricular hypertrophy
23. Role of Exercise Testing in the Evaluation of the Patient with Hypertrophic Cardiomyopathy
24. Shedding growth factors in cardiac hypertrophy
25. SIV Cardiomyopathy in Non-Human Primates
26. Src and Multiple MAP Kinase Activation in Cardiac Hypertrophy
27. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy
28. Surgical Approaches to Dilated Cardiomyopathy
29. Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy
30. The A-Type Lamins-Nuclear Structural Proteins as a Focus for Muscular Dystrophy and Cardiovascular Diseases
31. The emerging concept of mitochondrial cardiomyopathies
32. The failing heart
33. Viral myocarditis and dilated cardiomyopathy
2. Folic Acid Improves Endothelial Function in Coronary Artery Disease via Mechanisms Largely Independent of Homocysteine Lowering
3. Rate of endothelial expansion is controlled by cell
4. The Vesiculo：CVacuolar Organelle (VVO)-A New Endothelial Cell Permeability Organelle
2. New ideas about atrial fibrillation 50 years on
3. Use of Intracardiac Echocardiography to Guide Ablation of Atrial Fibrillation
4. Atrial fibrillation-where do we stand today
5. Structural remodelling during chronic atrial fibrillation
6. Atrial electrical remodelling and atrial fibrillation
7. Atrial fibrillation-from cells to computers
8. Atrial fibrillation-nonpharmacologic approaches
9. Catheter ablation of atrial fibrillation-challenges and promise
10. Cost-effective management of acute atrial fibrillation
11. Current perspectives on curative catheter ablation of atrial fibrillation
12. Current status of dual-sensor pacemaker systems for correction of chronotropic incompetence
13. Drug choices in the treatment of atrial fibrillation
14. Echocardiographic evidence of hemodynamic and clinical improvement in patients paced for heart failure
15. Effect of stored electrograms on management in the paced patient
16. Electrocardiographic remodeling in patients paced for heart failure
17. Establishing the link between a specific pathology and atrial fibrillation
18. Evidence rather than costs must guide use of the implantable cardioverter defibrillator
19. Evolving role of echocardiography in the management of atrial fibrillation
20. Formulation substitution and other pharmacokinetic variability
21. Hemodynamic sensors
22. Management and prevention of atrial fibrillation after cardiovascular surgery
23. Mapping-guided ablation of pulmonary veins to cure atrial fibrillation
24. Multisite atrial pacing-an option for atrial fibrillation prevention
25. Optimal method to achieve consistently low defibrillation energy requirements
26. Pacemaker automaticity
27. Pacing therapies in congestive heart failure II study
28. palliating the symptoms
29. Paroxysmal atrial fibrillation
30. Pharmacologic management of atrial fibrillation
31. Profiling risk from arrhythmic or hemodynamic death
32. Prospective randomized trials on pacing mode
33. Prothrombotic markers in atrial fibrillation-what is new
34. Rate smoothing with cardiac pacing for preventing torsade de pointes
35. Recent Fibrillation Studies
36. Reperfusion Arrhythmias and Sudden Cardiac Death-A Century of Progress Toward an Understanding of the Mechanisms
37. Role of molecular biology in identifying individuals at risk for sudden cardiac death
38. Screening and therapy for patients with nonsustained ventricular tachycardia
39. Should stimulation site be tailored in the individual heart failure patient
40. Should stimulation therapy for congestive heart failure be combined with defibrillation backup
41. Spatial and Temporal Organization in Ventricular Fibrillation
42. Structural remodelling during chronic atrial fibrillation
43. sudden death in high-risk family members-Brugada syndrome
44. Therapeutic decision tree for patients with sustained ventricular tachyarrhythmias or aborted cardiac arrest
45. therapeutic options and clinical decisions
46. Transvenous biventricular defibrillation
47. Transvenous left ventricular lead implantation with the EASYTRAK lead system-the European experience
2. Advances in the genetics of cerebrovascular disease and stroke
3. Advances in the molecular mechanisms of heart failure
4. Angiotensinogen Gene Core Promoter Variants and Non-Modulating Hypertension
5. Animal models of hypertrophic cardiomyopathy
6. Apoptosis and cardiomyopathy
7. Aspects of gene polymorphisms in cardiovascular disease-the renin-angiotensin system
8. atrial form function_Lessons from Human Molecular Genetics
9. Cardiomyopathy in animal models of muscular dystrophy
10. Development of genetic hypotheses in essential hypertension
11. DNA microarray analysis of gene expression in endothelial cells in response to 24-h shear stress
12. Endothelial Nitric Oxide Synthase Gene Sequence Variations and Vascular Disease
13. Expression profiling of cardiac genes in human hypertrophic cardiomyopathy
14. Familial dilated cardiomyopathy-from clinical presentation to molecular genetics
15. Gene Mutation in Cardiac Myosin Binding Protein C
16. Genetic Risk Factors for Venous Thrombosis
17. Good medicines for bad genes
18. Lipoprotein(a), Atherosclerosis, and Apolipoprotein(a) Gene Polymorphism
19. Models of dilated cardiomyopathy in the mouse and the hamster
20. Molecular aspects of arrhythmias associated with cardiomyopathies
21. Molecular biology of arrhythmic syndromes
22. On genetic and phenotypic variability of hypertrophic cardiomyopathy
23. The molecular pathogenesis of the Marfan syndrome
24. Molecular and Ionic Basis of Congenital Complete Heart Block
25. Molecular Clock Mechanisms and Circadian Rhythms Intrinsic to the Heart
26. Molecular Structure and Functional Role of Vascular Tight Junctions
27. Advances in cardiovascular genetics and embryology-role of transcription factors in congenital heart disease
28. Atrial Form and Function-Lessons from Human Molecular Genetics
29. Molecular and Ionic Basis of Congenital Complete Heart Block
30. Molecular Structure and Functional Role of Vascular Tight Junctions
31. New Aspect of the Research on Limb-Girdle Muscular Dystrophy 2A_A Molecular Biologic and Biochemical Approach to Pathology
32. Nuclear factor kappa-B and the heart
33. Phenotype-Driven Genetic Approaches in Mice; High-Throughput Phenotyping for Discovering New Models of Cardiovascular Disease
34. Phenotype-Driven Genetic Approaches in Mice_ High-Throughput Phenotyping for Discovering New Models of Cardiovascular Disease
35. The future of genetic association studies in hypertension_improving the signal-to-noise ratio
36. The Heart SNPs a Beat; Polymorphisms in Candidate Genes for Cardiovascular Disease
37. The Heart SNPs a Beat_ Polymorphisms in Candidate Genes for Cardiovascular Disease
38. concerning research in genetic markers of disease
39. Ethical and legal issues in genetic testing to
40. Genetic approaches for the investigation of genes associated with coronary heart disease
41. Genetics of coronary heart disease-Current knowledge and research principles
42. Genetics and dilated cardiomyopathy limitations of candidate gene strategies
43. Genetics of inflammation and risk of coronary artery diseasethe central role of interleukin-6
44. A Promising Genetic Approach to the Treatment of b-Thalassemia
45. Advances in molecular genetics and pathology of cerebrovascular disorders
46. MOLECULAR BASES OF CIRCADIAN RHYTHMS
47. Molecular genetic basis of sudden cardiac death
48. Molecular genetics of G proteins and atherosclerosis risk
49. Molecular regulation of lymphangiogenesis and targets for tissue oedema
50. Sterol Regulatory Element-binding Protein-1 as a Dominant Transcription Factor for Gene Regulation of Lipogenic Enzymes in the Liver
51. The LDL Receptor Gene Family-(Un)Expected Signal Transducers in the Brain
52. Troponin I Isoforms and Chimeras-Tuning the Molecular Switch of Cardiac Contraction
53. Tumors and the heart-molecular genetic advances
54. Genetic basis of syndromes associated with congenital heart disease
55. Mitochondria and the heart
56. Molecular genetics
57. Tumors and the heart-molecular genetic advances
58. Genomic and Proteomic Databases_ Large Scale Analysis and Integration of Data
2. Heart failure clinics organization, development, and experiences
3. Heart failure, an evolving field from drugs to novel nonpharmacologic strategies
4. Heart failure,Noninvasive assessment of hemodynamics an emphasis on bioimpedance cardiography
5. aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension
6. Bi-ventricular pacing in congestive cardiac failure. Current experience and future directions
7. Pulsatile Hemodynamics in Congestive Heart Failure
8. The prognosis of heart failure-the view from the real world
9. Aldosterone in Congestive Heart Failure
10. Alterations of endothelium-dependent and-independent regulation of coronary blood flow during heart failure
11. Biventricular Cardiac Pacing-Promising New Therapy for Congestive Heart Failure
12. Brachial Artery Elastic Mechanics in Patients With Heart Failure
13. Cardiomyopathy in animal models of muscular dystrophy
14. Catabolism in chronic heart failure
15. Congestive Heart Failure
16. Coronary heart disease, smoking and hypertension are the greatest risk factors for congestive heart failure
17. Cytokines as Emerging Targets in the Treatment of Heart Failure
18. Diastolic heart failure
19. drugs and devices in the treatment of chronic heart failure
20. Endothelial dysfunction in chronic heart failure
21. G protein-coupled receptor kinases-gotta real kure for heart failure
22. Genetic basis of syndromes associated with congenital heart disease
23. Guidelines for the diagnosis and treatment of chronic heart failure
24. Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult
25. Health-related quality of life measurement in heart failure-Challenges for the New Millennium
26. Impact of low level laser irradiation on infarct size in the rat following myocardial infarction
27. Individualized treatment of heart failure
28. Intravascular and intracardiac stents used in congenital heart disease
29. Mechanisms involved in the hemodynamic alterations in congestive heart failure as a basis for a rational pharmacological treatment
30. Neurohormonal regulation of myocardial cell apoptosis during the development of heart failure
31. New strategies for the management of acute decompensated heart failure-1
32. New strategies for the management of acute decompensated heart failure
33. New therapies for heart failure-is thalidomide the answer
34. Old and new controversies in the treatment of advanced congestive heart failure
35. Overview of the results of recent beta blocker trials
36. Oxidative Stress Hypothesis of Congestive Heart Failure
37. PATHOPHYSIOLOGICAL ROLE OF CYTOKINES IN CONGESTIVE HEART FAILURE
38. Perindopril treatment for congestive heart failure
39. Practical approaches to treating patients with acute decompensated heart failure
40. Progression of Heart Failure-Is Protein Kinase A Hyperphosphorylation of the Ryanodine Receptor a Contributing Factor
41. Pulmonary edema-new insight on pathogenesis and treatment-1
42. Pulmonary edema-new insight on pathogenesis and treatment
43. Quality of care and hospital readmission in congestive heart failure
44. Rationale for the use of combination ACEI-angiotensin II receptor blocker therapy in heart failure
45. reatment of Congestive Heart Failure
46. Role of neuropeptides in heart failure
47. Surgical issues in heart failure
48. Systematic review of the management of atrial fibrillation in patients with heart failure
49. The effects of angiotensin receptor antagonists on mortality and morbidity in heart failure
50. The Role of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure
51. The Role of Continuous Positive Airway Pressure in the Treatment of Congestive Heart Failure
52. Transcription Factors and Heart Failure
53. Unravelling the pathophysiology of heart failure through human genomics
54. Which-blocker for heart failure
55. heart failure B type natriuretic peptide levels for congestive heart failure
56. heart failure Health related quality of life measurement in heart failure-Challenges-for the new millennium
2. Physiologic basis for the treatment of pulmonary hypertension
3. Progress in, and future prospects for, the treatment of primary pulmonary hypertension
4. Pulse Pressure, Endothelium Function, and Arterial Stiffness in Spontaneously Hypertensive Rats
5. Renin：Cangiotensin：Csympathetic crosstalks in hypertension
6. Sympathetic modulation of blood pressure variability
7. The 2-adrenergic receptors in hypertension and heart failure-experimental and clinical studies
8. Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension
9. Management of patients with myocardial infarction and hypertension
10. Blood pressure in diabetic nephropathy-current controversies
11. Should patients with hypertension receive antithrombotic therapy
12. Circadian rhythms and clinical medicine with applications to hypertension
13. Cyclic and circadian variations in cardiovascular events
14. Pharmacology of cardiovascular chronotherapeutic agents
15. Our Major Challenges
16. a place for combining ACEI and AGTR of hypertension renal disease heart failure
17. A review of the medical treatment of primary aldosteronism
18. Abnormal Vascular Function and Hypertension in Mice Deficient in Estrogen Receptor
19. Ambulatory blood pressure measurements
20. Ambulatory blood pressure monitoring in children and adolescents_the future
21. Angiotensin II type 1 receptor gene polymorphisms in humans-physiology and pathophysiology of the genotypes
22. Angiotensin type 2 receptors
23. Anti-ischemic effects of angiotensin-converting enzyme inhibition in hypertension
24. Antihypertensive pharmacogenetics-getting the right drug into the right patient
25. Antihypertensive pharmacogenetics
26. Are angiotensin-converting enzyme inhibitors the best treatment for hypertension in type 2 diabetes
27. Arterial hypertension and cardiac arrhythmias
28. Association between blood pressure, the treatment of hypertension, and cardiovascular risk factors in women
29. Biology of hypertensive cardiopathy
30. Blood pressure and long-term coronary heart disease mortality in the Seven Countries Study
31. Calcium channel blockers in hypertension
32. Choice of drug treatment for obesity-related hypertension-where is the evidence
33. Choice of drug treatment for obesity-related hypertension
34. Clinical aspects of hypertensive myocardial fibrosis
35. cohort study of possible risk factors for over-reporting of antihypertensive adherence
36. Controlling hypertension in the elderly
37. Coronary benefits of calcium antagonist therapy for patients with hypertension
38. Does aspirin attenuate the effect of ACEI in hypertension or heart failure
39. Effects of antihypertensive drugs on vascular remodeling
40. Effects of lifestyle modification on treatment and prevention of hypertension
41. Ethnic differences in hypertension and blood pressure control
42. Exercise and hypertension
43. Fibrosis and hypertensive heart disease
44. Genetic forms of human hypertension
45. Growth in utero and blood pressure levels in the next generation
46. Heart, aging, and hypertension
47. Hypertension in end-stage renal disease patients
48. Intrarenal AT1 receptor and ACE binding in ANG II-induced hypertensive rats
49. Is microalbuminuria a predictor of cardiovascular and renal disease in patients with essential hypertension
50. Large multicentre hypertension trials
51. Long-term renal consequences of hypertension for normal and diseased kidneys
52. Molecular genetics of essential hypertension
53. Molecular genetics of human hypertension
54. Molecular mechanisms of sodium transport inhibition in proximal tubule during acute hypertension
55. Noninvasive imaging in congenital heart disease
56. Novel Signaling Pathways Contributing to Vascular Changes in Hypertension
57. Oxidative stress and vascular damage in hypertension
58. Possible Involvement of Rho-Kinase in the Pathogenesis of Hypertension in Humans
59. Preventing cardiovascular disease in hypertensive patients with type 2 diabetes_is there a superior antihypertensive therapy
60. Pro-inflammatory cytokines in patients with essential hypertension
61. Pulmonary vascular remodeling-a target for therapeutic intervention in pulmonary hypertension
62. Pulse pressure, arterial stiffness, and cardiovascular risk
63. Relation of high levels of high-density lipoprotein cholesterol to coronary artery disease and systemic hypertension
64. Renal blood flow autoregulation in blood pressure control
65. Renal endothelin in hypertension
66. Renal Transplantation Studies in Genetic Hypertension
67. Risk and benefit of treatment of isolated systolic hypertension in the elderly
68. Role of dopamine receptors in the kidney in the regulation of blood pressure
69. Role of nitric oxide in regulation of the renal medulla in normal and hypertensive kidneys
70. s It Time for a New Approach to the Initial Treatment of Hypertension
71. Salt and blood pressure
72. Salt and Hypertension-2
73. Salt and Hypertension
74. Silent ischaemia and hypertension
75. Step test in hypertension
76. The antihypertensive and renal effects of angiotensin II receptor antagonists
77. The clinical implication of tissue renin angiotensin systems
78. The Diastolic Blood Pressure in Systolic Hypertension
79. The role of size at birth and postnatal catch-up growth in determining systolic blood pressure_a systematic review of the literature
80. Therapeutic studies and arterial stiffness in hypertension_recommendations of the European Society of Hypertension
81. There is a non-linear relationship between mortality and blood pressure
82. Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension_a literature survey
83. What Is Goal Blood Pressure for the Treatment of Hypertension
84. hypertension place for combining ACEI and AT receptor antagonists in the treatment of hypertension or heart failure
85. The management of hypertension a review of current guidelines, their shortcomings and implications for the future
86. Normal Blood Pressure More High Than Normal
87. Diagnosis of myocardial ischemia in hypertensive patients
88. Blood Pressure, Cognitive Functions, and Prevention of Dementias in Older Patients With Hypertension
89. Lipoprotein Lipase Gene Mutations and the Genetic Susceptibility of Preeclampsia
90. The Cell Cycle can be a New Target for the Treatment of Cardiac Hypertrophy
91. A review of the medical treatment of primary aldosteronism
92. Aldosterone and the hypertensive kidney_its emerging role as a mediator of progressive renal dysfunction_a paradigm shift
93. Ambulatory blood pressure monitoring in children and adolescents-the future
94. Antihypertensive pharmacogenetics-getting the right drug into the right patient
95. Arterial hypertension and cardiac arrhythmias
96. Association between blood pressure, the treatment of hypertension, and cardiovascular risk factors in women
97. Choice of drug treatment for obesity-related hypertension-where is the evidence
98. Diagnosis of myocardial ischemia in hypertensive patients
99. Growth in utero and blood pressure levels in the next generation
100. Physiological and pathophysiological role of magnesium in the cardiovascular system-in hypertension
101. Preventing cardiovascular disease in hypertensive patients with type 2 diabetes
102. Silent ischaemia and hypertension
103. Sympathetic modulation of blood pressure variability
104. The future of genetic association studies in hypertension
105. The role of size at birth and postnatal catch-up growth in determining systolic blood pressure
106. Therapeutic studies and arterial stiffness in hypertension
107. Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension
108. Why are strokes related to hypertension
2. N-terminal proBNP-to identify post myocardial infarction left ventriular dysfunction
3. American College of Cardiology Committee for the Redefinition of Myocardial Infarction
4. Coronary stenting and platelet glycoprotein IIb-IIIa receptor blockade in acute myocardial infarction
5. Electrocardiographic diagnosis of acute myocardial infarction
6. Gene-Gene Interaction in the RAS System in the Predisposition to Myocardial Infarction
7. Impact of low level laser irradiation on infarct size in the rat following myocardial infarction
8. Infarct artery reocclusion after primary angioplasty therapy for acute myocardial infarction
9. Infarct artery reocclusion after primary angioplasty, stent placement, for acute myocardial infarction
10. inflammatory response in myocardial infarction-1
11. inflammatory response in myocardial infarction
12. INTER-HEAR-A global study of risk factors for acute myocardial infarction
13. Interventional procedures in acute myocardial infarction
14. Matrix Metalloproteinase Inhibition After Myocardial Infarction
15. Multimodality reperfusion therapy for acute myocardial infarction
16. Myocardial viability-impact on left ventricular dilatation after acute myocardial infarction
17. New Approaches to Diagnosis and Management of Unstable Angina and Non：CST-Segment Elevation Myocardial Infarction
18. Present treatment options for unstable angina and non-Q-wave myocardial infarction
19. Relation of antibiotic use to risk of myocardial infarction in the general population
2. Diagnosis of myocardial ischemia in hypertensive patients
3. Effects of myocardial ischemia and reperfusion on mitochondrial function and susceptibility to oxidative stress
4. NOS-Myocardial Ischemia
2. Constrictive pericarditis in the modern era-a diagnostic dilemma
3. Constrictive pericarditis in the modern era
4. Interleukin-6 Aggravates Viral Myocarditis
5. Troponins in pericarditis-implications for diagnosis and management of chest pains patients
2. Invited Review-Focal adhesion and small heat shock proteins in the regulation of actin remodeling and contractility in smooth muscle
3. Invited Review-Regulation of myosin phosphorylation in smooth muscle
4. Invited Review-Significance of spatial and temporal heterogeneity of calcium transients in smooth muscle
5. Mechanisms of calcium handling in smooth muscles
6. The circle of life-cell cycle regulation in airway smooth muscle
7. Time course and heterogeneity of contractile responses in cultured human airway smooth muscle cells
8. Arteriolar smooth muscle mechanotransduction-Ca2+ signaling pathways underlying myogenic reactivity
9. HSP20 phosphorylation in nitroglycerin-and forskolin-induced sustained reductions in swine carotid media tone
10. Insulin utilizes NO-cGMP pathway to activate myosin phosphatase via Rho inhibition
11. Roles of focal adhesion kinase and paxillin in the mechanosensitive regulation of myosin phosphorylation
2. Approaches to Identify, Validate, and Understand Ischemic Stroke Gene Expression
3. Narrowing the evidence：Cpractice gap
4. Management of shoulder pain in patients with stroke
5. A New Method for Predicting Recovery After Stroke
6. Acetaminophen for Altering Body Temperature in Acute Stroke
7. Aptiganel Hydrochloride in Acute Ischemic Stroke
8. Arterial dissection and stroke in children
9. Basis for primary prevention of stroke under a social health act
10. Choice of endpoints in antiplatelet trials-Which outcomes are most relevant to stroke patients
11. Dual Regulation of the Cerebral Microvasculature by Epoxyeicosatrienoic Acids
12. Dynamic Imaging of Cerebral Blood Flow Using Laser Speckle
13. HMG-CoA reductase inhibitors (statins)-A promising approach to stroke prevention
14. Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia
15. Lack of Clinical Significance of Early Ischemic Changes on Computed Tomography in Acute Stroke
16. Management of acute physiological parameters after stroke
17. NINDS-Sponsored Clinical Trials in Stroke
18. Pathophysiological and clinical aspects of breathing after stroke
19. Preventing Strokes by Lowering Blood Pressure in Patients With Cerebral Ischemia-Emerging Therapies
20. Programmed Cell Death in Cerebral Ischemia
21. Protein Kinase C and Cerebral Vasospasm
22. Reactive Oxygen Radicals in Signaling and Damage in the Ischemic Brain
23. Report of the National Institute of Neurological Disorders and Stroke Workshop on Perinatal and Childhood Stroke
24. Snoring, sleep apnoea and stroke
25. The evolution of stroke units?atowards a more intensive approach
26. Thrombolysis in acute ischaemic stroke
27. Why are strokes related to hypertension_Classic studies and hypotheses revisited
28. Why are strokes related to hypertension-Classic studies and hypotheses revisited
2. Clinical manifestations of myocardial stunning
3. Clinical pathophysiology of hibernating myocardium
4. Determinants of left ventricular systolic function after acute myocardial infarction
5. Evidence for stunned myocardium in humans-a 2001 update
6. Lessons from experimental models of hibernating myocardium
7. Pharmacologic treatment of the stunned myocardium
2. Activation of Factor IX by Factor XIa
3. Activation of the Platelet Collagen Receptor Integrin 21; Its Mechanism and Participation in the Physiological Functions of Pla
4. Activation of the Platelet Collagen Receptor Integrin a2b1_ Its Mechanism and Participation in the Physiological Functions of Platelets
5. Annexin II; A Mediator of the Plasmin-Plasminogen Activator System
6. Annexin II_ A Mediator of the Plasmin-Plasminogen Activator System
7. antithrombotics and anticoagulants-
8. antithrombotics and anticoagulants-Conclusion
9. antithrombotics and anticoagulants-Fibrin specificity of plasminogen activators, rebound generation of thrombin, and their therapeutic
10. antithrombotics and anticoagulants-New anticoagulants
11. antithrombotics and anticoagulants-New data in treatment of acute coronary syndromes
12. antithrombotics and anticoagulants-Pentasaccharide Org31540-SR90107A clinical trials update
13. antithrombotics and anticoagulantsRecent advances in anticoagulant therapy for acute coronary syndromes
14. AUTOSOMAL RECESSIVE DEFICIENCIES OF COAGULATION FACTORS
15. blood-Hemostasis and thrombosis-Acute bleeding complications in patients after bone marrow transplantation
16. blood-Hemostasis and thrombosis-Antithrombotic treatments in acute ischemic stroke
17. blood-Hemostasis and thrombosis-Catastrophic antiphospholipid syndrome
18. blood-Hemostasis and thrombosis-Diagnosis and incidence of inherited von Willebrand disease
19. blood-Hemostasis and thrombosis-Inherited thrombophilia and fetal loss
20. blood-Hemostasis and thrombosis-Mechanisms of platelet aggregation
21. blood-Hemostasis and thrombosis-Platelet glycoprotein polymorphisms as risk factors for thrombosis
22. blood-Hemostasis and thrombosis-Platelet kinetics in immune thrombocytopenic purpura and human immunodeficiency virus thrombocytopenia
23. blood-Hemostasis and thrombosis-Platelets, leukocytes, and coagulation
24. blood-Hemostasis and thrombosis-Role of blood coagulation factor XI in downregulation of fibrinolysis
25. blood-Hemostasis and thrombosis-The role of platelet collagen receptor
26. blood-Hemostasis and thrombosis-Use of recombinant factor VIIa in hereditary bleeding disorders
27. blood-Hemostasis and thrombosis-von Willebrand factor and thrombotic thrombocytopenic purpura
28. blood-Heparin-Binding Exosite of Factor Xa
29. blood-Platelet activation-assessment and quantification
30. blood-Role of Activation of the Coagulation Factor VIII in Interaction with vWf
31. blood-Role of Annexin II Tetramer in Plasminogen Activation
32. Catabolism of the Coagulation Factor VIII; Can We Prolong Lifetime of f VIII in Circulation
33. Catabolism of the Coagulation Factor VIII_ Can We Prolong Lif
34. Cellular Effects of Initiation of the Extrinsic Pathway of Blood coagulation
35. Current trends in the management of thromboembolic events
36. Dissociation of Thrombin's Substrate Interactions Using Site-Directed Mutagenesis
37. Factor VIIa-Induced Gene Expression; Potential Implications in Pathophysiology
38. Factor VIIa-Induced Gene Expression_ Potential Implications in Pathophysiology
39. Hemostasis and thrombosis-Circulating tissue factor and thrombosis
40. Heparin cofactor II inhibits arterial thrombosis after endothelial injury
41. Heparin-Binding Exosite of Factor Xa
42. Mapping of the Cryptic Integrin-Binding Site in Osteopontin Suggests a New Mechanism by Which Thrombin Can Regulate Inflammation and Tissue Repair
43. Platelets and the Injured Vessel Wall-Rolling into Action
44. Role of Activation of the Coagulation Factor VIII in Interaction with vWf, Phospholipid, and Functioning within the Factor Xase Complex
45. Role of Annexin II Tetramer in Plasminogen Activation
46. The Interaction between Anticoagulant Protein S and Complemen Regulatory C4b-binding Protein (C4BP)
47. The Urokinase Receptor Associated Protein (uPARAP-Endo180)_ A Novel Internalization Receptor Connected to the Plasminogen Activation System
48. Thrombopoietin-a pan-hematopoietic cytokine
49. THROMBOSPONDINS-Multifunctional Regulators of Cell Interactions
50. Tissue Factor in the Heart-Multiple Roles in Hemostasis, Thrombosis, and Inflammation
51. Tissue Factor, the Blood, and the Arterial Wall
52. Tissue Plasminogen Activator for the Treatment of Deep Venous Thrombosis of the Lower Extremity
2. Current approaches to minimally invasive aortic valve surgery
3. Current status of stentless aortic xenografts
4. Pulmonary homografts-current status
5. The surgical management of bacterial valvular endocarditis
6. Alternatives in selection of rings for mitral annuloplasty
7. Aortic valve replacement-current clinical practice and opportunities for quality improvement
8. Aortic valve replacment-an update at the turn of the millennium
9. Are the indications for tissue valves different in 2001 and to our cardiology colleagues
10. Defining ?＜minimally invasive?＼ in valvular heart disease
11. Pitfalls in surgical decision-making during mitral valve repair
12. Robotic cardiac valve surgery-transcending the technologic crevasse
13. Ventricular and Atrial Septal Defects
2. Churg-Strauss syndrome-update on recent developments
3. Cryoglobulinemia vasculitis
4. Giant cell arteritis
5. New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis
6. Pregnancy in vasculitis
7. Systemic vasculitis-new insights and emerging issues